Businessweek

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products. The company’s animal health business, operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. Its products are sold in approximately 130 countries. Human Pharmaceutical Products Neuroscience Products The company’s neuroscience products include Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the U.S. for the management of fibromyalgia and of chronic musculoskeletal pain due to chronic low back pain or chronic pain due to osteoarthritis; Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents, and in the U.S., in adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; Symbyax, for the treatment of bipolar depression and treatment-resistant depression; and Amyvid, a radioactive diagnostic agent approved in 2012 in the U.S. and 2013 in the European Union (EU) for positron emission tomography imaging of beta-amyloid neuritic plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Endocrinology Products The company’s endocrinology products include Humalog, Humalog Mix 75/25, and Humalog Mix 50/50, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Bydureon, for the treatment of type 2 diabetes; Tradjenta, for the treatment of type 2 diabetes; Jentadueto, a combination tablet of Tradjenta and metformin hydrochloride for use in the treatment of type 2 diabetes; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Humatrope, for the treatment of human growth hormone deficiency and certain pediatric growth conditions; and Axiron, a topical solution of testosterone, applied by underarm applicator, for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone. Oncology Products The company’s oncology products comprise: Alimta is for the first-line treatment, in combination with another agent, of advanced non-small cell lung cancer for patients with non-squamous cell histology; for the second-line treatment of advanced non-squamous non-small cell lung cancer; as monotherapy for the maintenance treatment of advanced non-squamous non-small cell lung cancer in patients whose disease has not progressed immediately following chemotherapy treatment; and in combination with another agent, for the treatment of malignant pleural mesothelioma. Gemzar is for the treatment of pancreatic cancer, in combination with other agents, for the treatment of metastatic breast cancer, non-small cell lung cancer, and advanced or recurrent ovarian cancer; and in the EU for the treatment of bladder cancer. Erbitux, indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers; and as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers. Cardiovascular Products The company’s cardiovascular products include Cialis, for the treatment of erectile dysfunction and benign prostatic hyperplasia; Effient, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), inc